4D Molecular Therapeutics (FDMT) Cash & Current Investments (2019 - 2026)

4D Molecular Therapeutics (FDMT) has reported Cash & Current Investments for 8 consecutive years, with $390.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 21.61% year-over-year to $390.9 million; the TTM figure through Mar 2026 stood at $390.9 million (up 21.61% YoY), while the FY2025 annual figure was $402.7 million, down 5.23% from the prior year.
• Cash & Current Investments eased to $390.9 million in Q1 2026 per FDMT's latest filing, from $402.7 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $541.9 million in Q2 2024 and bottomed at $200.5 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $337.9 million across 5 years, with a median of $310.3 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Current Investments jumped 162.36% — and 2025, when it tumbled 45.89%.
• 4D Molecular Therapeutics' Cash & Current Investments stood at $213.6 million in 2022, then soared by 34.97% to $288.2 million in 2023, then surged by 47.41% to $424.9 million in 2024, then decreased by 5.23% to $402.7 million in 2025, then decreased by 2.92% to $390.9 million in 2026.
• Business Quant data shows FDMT's Cash & Current Investments at $390.9 million in Q1 2026, $402.7 million in Q4 2025, and $305.1 million in Q3 2025.